Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07203833

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-07

144

Participants Needed

1

Research Sites

79 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.

CONDITIONS

Official Title

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults over 18 years.
  • Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.
  • Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T6.3) with a documented or suspected infection
  • Group 2: patients with shock defined by arterial hypotension requiring vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexia (T6). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock
Not Eligible

You will not qualify if you...

  • Pregnant women
  • Group 1: No evidence of suspected or documented infection
  • Group 2: Presence of fever and/or suspected infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Amiens-Picardie

Amiens, France, 80000

Actively Recruiting

Loading map...

Research Team

J

Julien Maizel, Pr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here